MX2020013833A - Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias. - Google Patents

Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias.

Info

Publication number
MX2020013833A
MX2020013833A MX2020013833A MX2020013833A MX2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A
Authority
MX
Mexico
Prior art keywords
methods
compositions
thalassemias
hemoglobinopathies
treatment
Prior art date
Application number
MX2020013833A
Other languages
English (en)
Inventor
Sean Carroll
Raffi Afeyan
Matthew Russell
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MX2020013833A publication Critical patent/MX2020013833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0606—Arginine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0612—Carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/062—Glutamine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0624—Histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0628—Leucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/063—Lysine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0642—Serine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0654—Valine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona composiciones y métodos para mejorar la disfunción de eritrocitos o tratar una hemoglobinopatía o una talasemia (por ejemplo, anemia de células falciformes o ß-talasemia).
MX2020013833A 2018-06-20 2019-06-19 Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias. MX2020013833A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687721P 2018-06-20 2018-06-20
US201962804879P 2019-02-13 2019-02-13
PCT/US2019/037925 WO2019246214A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the treatment of hemoglobinopathies and thalassemias

Publications (1)

Publication Number Publication Date
MX2020013833A true MX2020013833A (es) 2021-03-25

Family

ID=67482969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013833A MX2020013833A (es) 2018-06-20 2019-06-19 Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias.

Country Status (20)

Country Link
US (2) US11058654B2 (es)
EP (1) EP3809881A1 (es)
JP (1) JP2021528414A (es)
KR (1) KR20210022054A (es)
CN (1) CN112654263A (es)
AU (1) AU2019290620A1 (es)
BR (1) BR112020026110A2 (es)
CA (1) CA3104279A1 (es)
CL (1) CL2020003276A1 (es)
CU (1) CU20200106A7 (es)
EA (1) EA202190073A1 (es)
EC (1) ECSP20081995A (es)
IL (1) IL279467A (es)
JO (1) JOP20200325A1 (es)
MX (1) MX2020013833A (es)
PE (1) PE20210371A1 (es)
PH (1) PH12020552212A1 (es)
SG (1) SG11202012714QA (es)
TW (1) TW202015667A (es)
WO (1) WO2019246214A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN110678172A (zh) 2017-04-28 2020-01-10 胺细拉健康公司 用于治疗创伤性脑损伤的氨基酸组合物及其使用方法
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
US11679089B2 (en) 2018-06-20 2023-06-20 Axcella Health Inc. Methods of manufacturing amino acid compositions
US20230000808A1 (en) * 2019-12-06 2023-01-05 Axcella Health Inc. Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias
CN112336710A (zh) * 2020-12-27 2021-02-09 西北农林科技大学 谷氨酰胺在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用
TW202315605A (zh) 2021-07-26 2023-04-16 美商胺細拉健康公司 用於治療ｃｏｖｉｄ—１９急性後期後遺症的胺基酸組合物及方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US6028107A (en) 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
JP2004527501A (ja) 2001-03-05 2004-09-09 ピー． アーネスト，スティーヴン 経腸処方
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
EP2397128A1 (en) 2003-02-14 2011-12-21 Children's Hospital & Research Center at Oakland Use of L-arginine optionally combined with magnesium for the treatment of sickle cell disease and/or pulmonary hypertension
US20050070607A1 (en) 2003-08-19 2005-03-31 James Andrus N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
JP2005272410A (ja) * 2004-03-26 2005-10-06 Ajinomoto Co Inc 抗動脈硬化用及び／又は血液レオロジー改善用経口アミノ酸組成物
WO2006002096A2 (en) 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Low doses of l-citrulline for treating diseases
WO2006060793A2 (en) 2004-12-01 2006-06-08 Children's Hospital & Research Center At Oakland Diagnosis of conditions associated with decreased arginine bioavailability
RU2007143040A (ru) 2005-04-21 2009-05-27 Гленн А. ГОЛДШТЕЙН (US) Амид n-ацетилцистеина (амид nac) в лечении заболеваний и состояний, связанных с окислительным стрессом
US20120316121A1 (en) 2005-07-28 2012-12-13 Allen Ann De Wees Materials and Methods for Modulating Arginine Metabolism
JP5316918B2 (ja) * 2006-04-24 2013-10-16 味の素株式会社 透析患者用輸液剤
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
WO2008054788A2 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
WO2009149196A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc. Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
EP2779842B1 (en) 2011-11-15 2017-09-20 TIMA Foundation Composition for protection against cell-damaging effects
BR112014014765A8 (pt) 2011-12-19 2017-07-04 Emmaus Medical Inc métodos e composições para o tratamento da diverticulose
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
US9597367B2 (en) 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
US11026913B2 (en) 2013-09-05 2021-06-08 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
KR20160056941A (ko) 2013-09-25 2016-05-20 프로뉴트리아 바이오사이언시스, 인코퍼레이티드 당뇨병 및 비만의 예방 및 치료를 위한 조성물 및 제형, 그리고 글루코스 및 열량 제어에서 이들의 생성방법 및 용도
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
US10758569B2 (en) 2014-01-13 2020-09-01 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
WO2015127163A1 (en) 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
ES2683184T3 (es) * 2014-04-30 2018-09-25 F. Hoffmann-La Roche Ag Inhibidores de GLyT1 para su uso en el tratamiento de trastornos hemáticos
EP3151671A4 (en) 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
US9822190B2 (en) 2015-01-29 2017-11-21 Shaker A. Mousa Compositions and method for anti-sickling of red blood cells in sickle cell disease
AU2017306756B2 (en) 2016-08-05 2022-10-27 Fresenius Kabi Deutschland Gmbh Glutamine for preserving, improving or restoring kidney function
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AR111082A1 (es) 2017-02-27 2019-05-29 Univ Vanderbilt Citrulina para el tratamiento de la crisis de células falciformes
CN110678172A (zh) 2017-04-28 2020-01-10 胺细拉健康公司 用于治疗创伤性脑损伤的氨基酸组合物及其使用方法
CA3072092A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. Branched-chain amino acids for the treatment of neuronal injury
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
US11679089B2 (en) 2018-06-20 2023-06-20 Axcella Health Inc. Methods of manufacturing amino acid compositions
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
US11298332B2 (en) 2018-06-20 2022-04-12 Axcella Health Inc. Compositions for therapy and health containing amino acids with bitter taste
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias

Also Published As

Publication number Publication date
US20190388376A1 (en) 2019-12-26
WO2019246214A1 (en) 2019-12-26
BR112020026110A2 (pt) 2021-03-16
PH12020552212A1 (en) 2021-08-16
TW202015667A (zh) 2020-05-01
US11058654B2 (en) 2021-07-13
JP2021528414A (ja) 2021-10-21
CL2020003276A1 (es) 2021-07-09
EP3809881A1 (en) 2021-04-28
EA202190073A1 (ru) 2021-04-12
WO2019246214A8 (en) 2020-02-20
IL279467A (en) 2021-01-31
AU2019290620A1 (en) 2021-01-14
ECSP20081995A (es) 2021-01-29
PE20210371A1 (es) 2021-02-26
US20210290574A1 (en) 2021-09-23
CN112654263A (zh) 2021-04-13
CA3104279A1 (en) 2019-12-26
SG11202012714QA (en) 2021-01-28
JOP20200325A1 (ar) 2020-12-14
CU20200106A7 (es) 2021-08-06
KR20210022054A (ko) 2021-03-02

Similar Documents

Publication Publication Date Title
MX2020013833A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
PH12018501226A1 (en) Methods for treating huntingtons disease
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2020010369A (es) Particulas implantables y metodos relacionados.
WO2018134787A3 (en) Compositions and methods for the depletion of cd137+ cells
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
PH12021550558A1 (en) Modulators of pnpla3 expression
CR20200631A (es) Modulares de la expresión de apol1
PH12019502174A1 (en) Modulators of pcsk9 expression
ZA202004679B (en) Regeneration of genetically modified plants
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
PH12021551053A1 (en) Modulators of irf5 expression
MX2020013510A (es) Composiciones para tratamiento, y metodos para fabricar y usar las mismas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
MX2020010721A (es) Moduladores de la expresion de ezh2.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
AR117593A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias